Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector
Executive Summary
The rapidly evolving stem cell space may have matured to the level where a single company's misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following the mixed results of Osiris Therapeutics' Prochymal stem cell therapy in an interim look at a study in chronic obstructive pulmonary disease.